An exploratory study evaluated the 30 most commonly reported medications in the United States food and drug administration’s adverse event reporting system that are associated with the occurrence of kidney stones DOI Creative Commons

Erhao Bao,

Yang Yang,

Jiang Binglei

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Dec. 18, 2024

Objective This research project aimed to identify and analyze the top 30 drugs most commonly associated with kidney stone formation using data from U.S. Food Drug Administration’s Adverse Event Reporting System (FAERS) database. The study will focus on determining reported Odds ratio (ROR) Proportional Report (PRR) of each identified drug assess its potential risk contributing development stones in order effectively manage reduce overall burden worldwide. Background Kidney are a common urinary system disease, their is influenced by multiple factors, including medications, metabolic syndrome, environmental genetic susceptibility, tract abnormalities, obstructive pathology. Among these medications an important clearly defined cause formation. Currently, drug-induced account for 1%–2% all cases stones. Although proportion may appears modest, contribution prevalence should not be overlooked. high incidence frequent recurrence pose significant challenges prevention efforts. Therefore, thorough understanding which trigger crucial managing reducing this global health issue. Method utilized FDA database maintained Administration extract raw 1 January 2010, 31 March 2024. Duplicate was removed following FDA-recommended method. Subsequently, related extracted linking DEMO table, DRUG REAC table specific primaryid numbers, resulting total 37,781 records 37,027 demographic records. sorted based frequency stones, were selected analysis. primary analytical methods employed disproportionality analyses, calculating Ratio 95% Confidence Interval (CI) reveal association between adverse events. Results We ranked ROR PRR values. three Atazanavir (ROR 46.35, CI 43–50, 44.9), Topamax 19.44, 17.66–21.40, 19.19), Prevacid 12.67, 11.62–13.82, 12.57). categories antiretroviral drugs, proton pump inhibitors, antiepileptic drugs. Conclusion Our has summarized list Clear caused can likelihood patients developing condition. Clinical doctors keep vigilant during diagnosis treatment processes, communicate relevant information patients.

Language: Английский

Safety Profile and Suicidality Associated with the Use of Esketamine in the Treatment of Major Depressive Disorder in European Countries: An EudraVigilance Database Analysis DOI Creative Commons
Ilaria Ammendolia, Carmen Mannucci, Emanuela Esposito

et al.

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(5), P. 702 - 702

Published: May 9, 2025

Background/Objective: Major depressive disorder (MDD) is a common mental disorder, with significant portion of patients developing treatment-resistant depression (TRD). Esketamine an antagonist the N-methyl-D-aspartate receptor indicated as nasal spray in combination other antidepressants for adults TRD. Signals suspected adverse reactions (SARs) to esketamine from EudraVigilance database European countries were analyzed more defined safety profile this drug real world. Methods: SARs reported data system analyzed, and disproportionality analysis indicating suicidality esketamine, comparison fluoxetine venlafaxine, was performed. Results: Increases blood pressure (15.4%) dissociation (15.0%) most frequently SARs. The sex distribution indicates prevalence women, except increased completed suicide, which signaled men, while (18–64 years) elders (65–85 ages largest number esketamine. results indicate existence potential increase risk suicide depressed taking when compared venlafaxine. Conclusions: Apart carefulness due known limitations pharmacovigilance research conducted by using systems spontaneous signals SARs, points toward need greater attention being paid following prescription subjects. In regard, regulatory agencies also recommend, history suicide-related events or those exhibiting degree suicidal ideation prior beginning treatment should receive careful monitoring during treatment.

Language: Английский

Citations

1
Inhibition Mechanism of Ketamine‐Apatinib by CYP2C9 and 3A4: A Prediction of Possible Drug‐Drug Interaction DOI
Xiang Zheng, Haiyan Chen, Dan Lin

et al.

Biopharmaceutics & Drug Disposition, Journal Year: 2025, Volume and Issue: unknown

Published: May 21, 2025

ABSTRACT Most cancer patients experience severe pain, and apatinib, a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, demonstrates therapeutic efficacy against gastric cancer. Ketamine, psychotropic drug used for pain relief, exhibits potential in inhibiting progression but is associated with dose‐dependent adverse effects including neurological toxicity dependency. Thus, clarifying whether apatinib influences ketamine therapy when co‐administered critical. In this study, we investigated apatinib's inhibitory on metabolism using CYP2C9 CYP3A4 isoform assays. Results showed that exerted inhibition of metabolism, acted as noncompetitive inhibitor CYP2C9*1, CYP2C9*16, rat liver microsomes (RLM), competitive CYP2C9*3 CYP2C9*13, mixed‐model four alleles (*1, *4, *18, *23). Molecular docking revealed stronger binding affinity (−10.4 kcal/mol) to CYP3A4*1 than (−6.9 kcal/mol). Consequently, co‐administration may increase risk poor metabolizers (PMs), warranting vivo validation their interaction.

Language: Английский

Citations

0
Beyond NMDA Receptors: A Narrative Review of Ketamine’s Rapid and Multifaceted Mechanisms in Depression Treatment DOI Open Access

Z Antoś,

Xawery Żukow,

Laura Bursztynowicz

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(24), P. 13658 - 13658

Published: Dec. 20, 2024

The rising prevalence of depression, with its associated suicide risk, demands effective fast-acting treatments. Ketamine has emerged as promising, demonstrating rapid antidepressant effects. While early studies show swift mood improvements, precise mechanisms remain unclear. This article aims to compile and synthesize the literature on ketamine's molecular actions. primarily works by antagonizing NMDA receptors, reducing GABAergic inhibition, increasing glutamate release. enhanced activates AMPA triggering crucial downstream cascades, including BDNF-TrkB mTOR pathways, promoting synaptic proliferation regeneration. Moreover, neuroimaging have demonstrated alterations in brain networks involved emotional regulation, Default Mode Network (DMN), Central Executive (CEN), Salience (SN), which are frequently disrupted depression. Despite promising findings, reveals significant inaccuracies gaps understanding full scope therapeutic potential. For instance, ketamine engages opioid insinuating a permissive role system amplifying effects, albeit does not operate direct agonist. Further exploration is requisite comprehensively ascertain safety profile, long-term efficacy, impact genetic determinants, such BDNF polymorphisms, treatment responsiveness.

Language: Английский

Citations

2
An exploratory study evaluated the 30 most commonly reported medications in the United States food and drug administration’s adverse event reporting system that are associated with the occurrence of kidney stones DOI Creative Commons

Erhao Bao,

Yang Yang,

Jiang Binglei

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Dec. 18, 2024

Objective This research project aimed to identify and analyze the top 30 drugs most commonly associated with kidney stone formation using data from U.S. Food Drug Administration’s Adverse Event Reporting System (FAERS) database. The study will focus on determining reported Odds ratio (ROR) Proportional Report (PRR) of each identified drug assess its potential risk contributing development stones in order effectively manage reduce overall burden worldwide. Background Kidney are a common urinary system disease, their is influenced by multiple factors, including medications, metabolic syndrome, environmental genetic susceptibility, tract abnormalities, obstructive pathology. Among these medications an important clearly defined cause formation. Currently, drug-induced account for 1%–2% all cases stones. Although proportion may appears modest, contribution prevalence should not be overlooked. high incidence frequent recurrence pose significant challenges prevention efforts. Therefore, thorough understanding which trigger crucial managing reducing this global health issue. Method utilized FDA database maintained Administration extract raw 1 January 2010, 31 March 2024. Duplicate was removed following FDA-recommended method. Subsequently, related extracted linking DEMO table, DRUG REAC table specific primaryid numbers, resulting total 37,781 records 37,027 demographic records. sorted based frequency stones, were selected analysis. primary analytical methods employed disproportionality analyses, calculating Ratio 95% Confidence Interval (CI) reveal association between adverse events. Results We ranked ROR PRR values. three Atazanavir (ROR 46.35, CI 43–50, 44.9), Topamax 19.44, 17.66–21.40, 19.19), Prevacid 12.67, 11.62–13.82, 12.57). categories antiretroviral drugs, proton pump inhibitors, antiepileptic drugs. Conclusion Our has summarized list Clear caused can likelihood patients developing condition. Clinical doctors keep vigilant during diagnosis treatment processes, communicate relevant information patients.

Language: Английский

Citations

0